IVF company Virtus Health has withdrawn its offer to acquire rival Adora Fertility from Healius, citing the competition regulator’s opposition to the takeover.
Indian generics giant Dr Reddy’s Laboratories must give Bristol-Myers Squib unit Celgene Corporation three months’ notice before deciding to sell generic versions of blockbuster cancer drug Revlimid in Australia.
The ACCC has been accused of running a “experimental test case” that tries to fit the shares market within the scope of the Competition and Consumer Act with its criminal cartel case against Citigroup, Deutsche Bank and several prominent banking executives over a $2.5 billion ANZ share placement.
JPMorgan Australia chairman Rob Priestley told Citigroup and Deutsche Bank executives not to “panic” about picking up a shortfall in the sale of ANZ shares, a court has heard in the ACCC’s criminal cartel case over a $2.5 billion ANZ share placement.
A senior ACCC officer tried to dissuade ASIC from investigating alleged insider trading by JPMorgan because of fears it would “upset” the competition regulator’s criminal cartel case over a $2.5 billion ANZ share placement, a court has heard.
Bristol-Myers Squib unit Celgene Corporation has sued Indian generics giant Dr Reddy’s Laboratories for allegedly threatening to infringe eight patents for its blockbuster cancer drug Revlimid, which raked in US$12 billion for the US-based company in revenue last year.
A judge has rejected part of IVF provider Virtus Health’s bid for redactions in a recent decision from the court temporarily blocking the company from purchasing rival Adora Fertility, saying some of the confidentiality claims were “staggering” and “border on ridiculous.”
A court has shut down Facebook’s renewed push to cut off Melbourne-based content strategists Sked Social from posting on Instagram on behalf of its clients, with a judge saying the social media giant’s justification for varying the injunction order was “flimsy and possibly strategic”.
The Australian Competition and Consumer Commission has won an injunction to stop Virtus from completing the purchase of rival Adora Fertility until a court has ruled on the competition regulator’s challenge to the acquisition.
IVF provider Virtus Health would be “the author of its own fate” if its proposed acquisition of rival Adora Fertility flopped, a judge has said in hearing the ACCC’s bid for a temporary injunction blocking completion of the planned purchase.